Figure 1
From: Endothelial cell metabolism: parallels and divergences with cancer cell metabolism
Rationale to target EC metabolism—a hypothesis. Figure top: With time, the conventional anti-VEGF antiangiogenic treatment suffers from increasing resistance due to a shift towards alternative pro-angiogenic molecules of potentially various origins. Figure bottom: The antimetabolism treatment bypasses this problem by targeting the PFKFB3 protein downstream of the angiogenic signaling pathways. The blockage of PFKFB3 with 3PO results in a reduction of glycolysis levels and a subsequent halt of the angiogenic process. 3PO 3-(3-pyridinyl)-1-(4-pyridinyl)-2-propen-1-one, PFKFB3 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase-3, VEGF vascular endothelial growth factor, VEGFR2 vascular endothelial growth factor receptor 2.